Free trade agreements and TRIPS-plus measures

International Journal of Intellectual Property Management

Volumn 1, Issue 1-2, 2006, Pages 150-172

  Rossi, Francisco ^a  

^a UNDP   (Brazil)

Author keywords

Drug access; Free Trade Agreements; IP and Public health; Pharmaceuticals; TRIPS plus

Indexed keywords

EID: 34748831317     PISSN: 14789647     EISSN: 14789655     Source Type: Journal    
DOI: 10.1504/IJIPM.2006.011027     Document Type: Article

References (11)

1. Avafia, T. (2004) The Potential Impact of the US-SACU FTA Negotiations on Public Health Issues in Southern Africa, TRALAC.
2. Baker, B. (2004) Arthritic Flexibilities for Accessing Medicines. Analysis of the WTO Action Regarding Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, Article commissioned by the United Nations Millennium Development Goals project.
3. Bermúdez, J., Olivera, M.A. and Chaves, G. (2004) 'Intellectual property in the context of WTO TRIPS agreement. What is at stake?', Intellectual Property in the Context of WTO TRIPS Agreement: Challenges for Public Health. Fiocruz-ENSP-PAHO-WHO, Rio de Janeiro.
4. Correa, C. (2001) Integrating Public Health Concerns into Patent Legislation in Developing Countries, South Centre, Geneva.
5. Drahos, P. et al. (2004) The FTA and the PBS, A submission to the Senate Select Committee on the US-Australia Free Trade Agreement Available at www.aph.gov.au/senate/comitee/freetrade/-ctee
6. Fármacos Electronic Bulletin (2002) Cuanto Cuesta un Medicamento? (How Much Does it Cost to Produce a New Medicine?), Vol. 5, No. 4, September, www.boletinfarmacos.org.
7. Goozner, M. (2004) The 800 Million Pill. The Truth Behind the Cost of New Drugs, The University of California Press, Berkeley. CA.
8. Outterson, M.K. (2004) 'Free trade in pharmaceuticals', Medical Journal of Australia, Vol. 181, No. 5, pp.260, 261.
9. Public Citizen (2001) Drug Industry Most Profitable Again, Congress Watch, 11th April, available at www.citizen.org.
10. Schondelmeyer, S.W. (2000) Competition and Pricing Issues of the Pharmaceutical Market, Prime Institute, University of Minnesota, Note by Public Citizen based on figures from Fortune (1958-1999).
11. Vivas, D. (2003) Regional and Bilateral Agreements and TRIPS-Plus World, Quaker United Nations Office, Geneva, Switzerland.